Nutriband Inc. (NASDAQ: NTRB)

The QualityStocks Daily Newsletter would like to spotlight Nutriband Inc. (NASDAQ: NTRB).

Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high

Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversion, misuse, abuse and accidental exposure

Nutriband's Aversa(TM) fentanyl patch is estimated to have a market potential of $80 million to $200 million annually within five years of launch

Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal technologies to deliver medications that require careful balancing of patient access with strong mitigation against misuse.

Nutriband Inc. (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA™ technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China, with recent extensions into Macao.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

In February 2025, the company formalized its product development partnership with Kindeva Drug Delivery through a long-term exclusive agreement. The collaboration supports the commercial pathway for AVERSA Fentanyl by leveraging Kindeva’s FDA-approved transdermal fentanyl patch system.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl. In subsequent updates, Nutriband confirmed that the NDA submission remains the company’s primary focus and is backed by a strong cash position.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

In support of this commercialization strategy, Nutriband closed an $8.4 million private placement in April 2024 to fund development activities related to AVERSA Fentanyl. The company also licensed Bitrex®, a widely used aversive agent, to enhance the deterrent profile of its patch formulation.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

Nutriband Inc. (NASDAQ: NTRB), closed Wednesday's trading session at $6.95, up 0.433526%, on 22,866 volume. The average volume for the last 3 months is 116,385 and the stock's 52-week low/high is $3.7223/$11.78.

Recent News

• Nutriband Inc. (NASDAQ: NTRB) - Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech
• Nutriband Inc. (NASDAQ: NTRB) Aligns Shareholder Value with FDA Milestone
• BioMedNewsBreaks - Nutriband Inc. (NASDAQ: NTRB): Innovation Meets Science Through Scalable Platform  

Safe Pro Group Inc. (NASDAQ: SPAI)

The QualityStocks Daily Newsletter would like to spotlight Safe Pro Group Inc. (NASDAQ: SPAI).

Safe Pro Group (NASDAQ: SPAI) , a leader in AI-powered defense and security solutions, welcomed the FAA's proposed rules to streamline Beyond Visual Line of Sight (BVLOS) drone operations. The Company expects the move will accelerate adoption of its computer vision and object detection technologies across government, public, and commercial sectors. Safe Pro's Airborne Response unit is a top provider of drone-based infrastructure inspections in Florida, and its AI technology has been field-tested in Ukraine to detect landmines and threats with high-speed accuracy. The Company is integrating these capabilities to expand services in public safety, disaster response, and environmental protection.

To view the full press release, visit https://ibn.fm/F6QH9

Safe Pro Group Inc. (NASDAQ: SPAI) is a mission-driven technology company delivering advanced AI-powered security and defense solutions. It is focused on serving customers in the defense, homeland security, humanitarian, law enforcement, and commercial markets where its AI, drone-based services and ballistic protective gear can synergistically deliver safety and operational efficiency.

At the heart of Safe Pro’s mission is its patented artificial intelligence (AI), machine learning (ML), deep learning and applied computer vision software technology. These tools are currently being used to rapidly detect small objects in drone-based video and imagery such as landmines and unexploded ordnance (UXO), enabling safer and more efficient field operations across global conflict and post-conflict zones and supporting efforts to improve the reliability of critical infrastructure. The company’s vision is to lead the evolution of security and threat detection through AI innovation, while its mission is to empower governments, enterprises, and humanitarian organizations with tools to respond to evolving threats at scale.

With a team of leaders and subject matter experts drawn from the defense, technology, and public safety sectors, Safe Pro Group delivers U.S.-developed next-generation AI and drone services through its Safe Pro AI and Airborne Response units and high-performance, American-made ballistic protective solutions through its Safe-Pro USA subsidiary.

The company is headquartered in Aventura, Florida.

Products

Safe Pro Group’s three business units operate across software, hardware, and field services to deliver a comprehensive suite of solutions. Each division plays a distinct role in supporting defense, humanitarian and public safety missions around the world.

Safe Pro AI

Safe Pro AI’s core AI-powered computer vision technology enables the rapid analysis of drone-based imagery to autonomously detect objects of interest. Its flagship product, SpotlightAI™ can detect and label over 150 types of explosive threats including landmines, cluster munitions, and unexploded ordnance (UXO). Built on more than two years of real-world usage in Ukraine and now including additional imagery being gathered from the Asian-Pacific region and Africa, SpotlightAI™ rapidly processes and creates high-resolution maps supported by the hyper scalability of the Amazon Web Services (AWS) cloud or detects threats in real-time locally through its OnSite Windows-based software application. Today, the platform boasts one of the world’s largest datasets built on over 1.6 million real-world battlefield images from Ukraine, identifying 28,000+ threats across more than 6,750 hectares, an area equivalent in size to Manhattan.

Airborne Response

Airborne Response is a leading provider of mission critical drone services using U.S. Government-compliant small uncrewed aircraft systems (sUAS) (drones). It serves enterprises in utilities & telecom and insurance with a full-range of drone-based critical infrastructure inspection and monitoring solutions as well as Drone-as-a-First Responder (DFR) services for law enforcement and public safety. It provides customers with actionable intelligence though data capture, analytics and processing powered by AI.

Safe-Pro USA

Safe-Pro USA manufactures ultra-premium, American-made ballistic protection systems including advanced body armor and ballistic plates as well as complete Explosive Ordnance Disposal (EOD) suits, demining aprons, and bomb blankets. All products exceed U.S. and NATO standards and are designed, engineered, and produced in the U.S., supporting customers across military, humanitarian, and law enforcement sectors.

Market Opportunity

Harnessing its patented, real-time, AI-powered processing of drone-based imagery, Safe Pro is creating a uniquely powerful ‘Next-Gen’ approach to situational awareness supporting ground-based personnel in safely completing their defense/military, humanitarian, law enforcement & commercial missions.

The global threat posed by landmines and UXO spans nearly 60 countries, affecting millions of civilians and imposing significant economic burdens, particularly in agriculture and infrastructure. In Ukraine alone, the contamination of 17 million hectares has resulted in $50+ billion in agricultural losses, with World Bank estimates projecting $30 billion needed in demining costs. According to the Landmine Monitor 2024, regions in Asia, Africa, and Latin America continue to report high casualty rates.

Safe Pro is positioned to capture a portion of the $15 billion+ global defense tech market, especially in AI-driven battlefield intelligence, drone surveillance, and threat detection. As a U.S.-based AI and defense technology provider with a HUBZone-certified manufacturing arm, Safe Pro is eligible for federal and state procurement programs, public safety grants, and critical infrastructure contracts, as well as global humanitarian demining efforts.

Leadership Team

Dan Erdberg, Chairman and CEO, brings over 20 years of experience as a C-level technology executive. He has led multiple Nasdaq listings in the drone, 5G, and satellite communications sectors, raised over $50 million in growth capital, and spearheaded Safe Pro Group’s corporate strategy and acquisitions.

Theresa Carlise, Chief Financial Officer, has more than 30 years of experience in financial leadership roles for public companies. Her expertise includes equity transactions, strategic planning, and financial restructuring. She served as Chief Financial Officer, Secretary, Treasurer and Director of various publicly traded companies within the retail, telecommunications, distribution, transportation, mortgage banking and construction sectors.

Pravin Borkar, CTO and Director (President, Safe-Pro USA), has over 30 years of experience in the engineering and manufacturing of ballistic protection systems for the U.S. Department of Defense. He has developed armor solutions for personnel and aircraft platforms including the CH-53 and Blackhawk.

Christopher Todd, President (Airborne Response), is a drone industry veteran and Certified Emergency Manager (CEM®) with more than 30 years of experience. He founded Airborne Response and is President of AUVSI Florida, with expertise in public safety drone deployment and emergency response.

Safe Pro Group Inc. (NASDAQ: SPAI), closed Wednesday's trading session at $3.84, up 5.4945%, on 228,437 volume. The average volume for the last 3 months is 257,857 and the stock's 52-week low/high is $1.47/$6.4999.

Recent News

• Safe Pro Group Inc. (NASDAQ: SPAI) - InvestorNewsBreaks - Safe Pro Group Inc. (NASDAQ: SPAI) Applauds FAA Proposal to Normalize BVLOS Drone Operations
• Safe Pro Group Inc.'s (NASDAQ: SPAI) Drone-Based AI Tech Selected for Next Year's U.S. Army Futures Command Experiment
• TechMediaBreaks - Safe Pro Group Inc. (NASDAQ: SPAI) Selected for U.S. Army Futures Command Warfighting Experiment 

Calidi Biotherapeutics Inc. (NYSE American: CLDI)

The QualityStocks Daily Newsletter would like to spotlight Calidi Biotherapeutics Inc. (NYSE American: CLDI).

A recent genetic discovery has the potential to boost the effectiveness of cancer immunotherapy treatments. According to a study published in the journal Nature, the genetic discovery may improve cancer treatment outcomes in certain patients. Researchers stumbled upon the promising clue while they studied treatment outcomes in ovarian clear cell carcinoma (OCCC) patients post-immunotherapy. The study was co-authored by Emily Hinchcliff, MD, an assistant professor of Obstetrics and Gynecology at Northwestern Medicine's Division of Gynecologic Oncology. She notes that conventional cancer treatments such as radiation and chemotherapy are rarely effective against OCCC, an aggressive but rare form of ovarian cancer that is often unresponsive to conventional treatments. Immunotherapy also has a low success rate against OCCC and only works for a few patients, Hinchcliff says. If successful, this research could pave the way for more personalized immunotherapy treatments and offer hope to patients with aggressive cancers that currently lack effective therapeutic options. By unlocking the potential of specific genetic mutations and their associated molecular pathways, scientists may accelerate the development of next-generation cancer therapies and improve survival outcomes worldwide. With many teams, such as the one at Calidi Biotherapeutics Inc. (NYSE American: CLDI), working to bring immunotherapy to more cancer patients, the future of oncology looks brighter than it was decades ago.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology that empowers the immune system to combat cancer. Calidi’s innovative, off-the-shelf cell-based platforms use allogeneic stem cells to deliver potent oncolytic viruses (OVs) across multiple oncology indications, including high-grade glioma (brain cancers) and solid tumors. In addition, Calidi has presented a breakthrough systemic technology, RTNova, which utilizes an exteracellular enveloped virotherapy. RTNova is pre-clinical and has been extremely well-received by market analysts and large-cap biopharma – opening the door for potential collaboration.

These cell-based platforms are engineered to protect, amplify, and enhance the efficacy of oncolytic viruses, resulting in improved patient safety and potentially advancing treatment outcomes for metastatic disease. By employing a dual approach that combines OV delivery with immune activation, Calidi’s therapies aim to not only treat but potentially prevent the spread of metastatic cancers.

The company’s development pipeline leverages this technology to address pressing needs in cancers such as glioblastoma (brain cancer), metastatic melanoma, triple-negative breast cancer, head & neck cancer, and lung cancer. Calidi’s approach has shown early signals of efficacy and safety, establishing it as a distinctive player in the growing OV market, which is projected to increase significantly in value over the next decade.

Calidi is headquartered in San Diego, California.

Products

Calidi’s product pipeline includes advanced cell-based platforms targeting a variety of oncology indications, each designed to harness the power of oncolytic virotherapy for improved cancer treatment outcomes.

• NeuroNova (CLD-101): A platform designed for treating high-grade gliomas (HGG), NeuroNova employs neuronal stem cells combined with an engineered adenovirus (CRAD-s-Pk7) to selectively target glioma cells. After a successful Phase 1 safety study in newly diagnosed HGG, NeuroNova has now progressed into Phase 1/1b trials for recurrent cases. FDA clearance for a Phase 1b/2 trial at Northwestern University was received in September 2024, with patient enrollment expected to begin in Q1 2025. This trial will utilize multiple-dose intracerebral administration to maximize safety and efficacy in newly diagnosed HGG patients.
• SuperNova (CLD-201): Built on Calidi’s foundational technology, SuperNova utilizes an engineered Vaccinia virus (CAL1) delivered via allogeneic adipose-derived mesenchymal stem cells to target advanced solid tumors, including head & neck, triple-negative breast cancer, and soft tissue sarcomas. Early studies with autologous stem cells demonstrated both safety and promising efficacy, and Calidi plans to begin a Phase 1 trial with multiple dose regimens for SuperNova in the coming months.
• RTNova (CLD-400): Calidi’s systemic delivery platform for lung and metastatic cancers, RTNova employs an extracellular enveloped virotherapy (envRT-01) technology for intravenous (IV) administration, simplifying the treatment process and expanding its potential applications. Currently in preclinical stages, RTNova focuses on demonstrating efficacy and safety through systemic administration. A clinical trial targeting metastatic lung cancer is anticipated for Q2 2026, using a single-arm monotherapy with dose escalation. Calidi has partnered with SIGA Technologies (NASDAQ: SIGA) to support the development of this program.

Market Opportunity

The global oncology drugs market was valued at $201.75 billion in 2023 and is projected to grow to $518.25 billion by 2032, with a CAGR of 11.3%. The oncolytic virotherapy market in particular is growing rapidly, driven by increasing approval rates and significant unmet needs.

The market for OV treatments is expected to expand from one approved product generating $150 million in the U.S. in 2021 to 6-8 approved therapies generating $2.4 billion by 2030. As a leader in OV technology, Calidi is well-positioned to address these high-demand areas in oncology.

Alongside global trends, the American Cancer Society projects nearly two million new cancer diagnoses in the U.S. in 2024, reflecting a 28% increase since 2010. This underscores the urgent need for novel therapies that not only treat disease progression but also enhance patient quality of life, reinforcing the demand for Calidi’s innovative approaches.

Management Team

Allan Camaisa, CEO, Chairman, and co-founder, is a seasoned leader with extensive experience in scaling businesses to successful exits. Mr. Camaisa previously led High Technology Solutions, growing it from two employees to over 500 with $50 million in revenue. He also served as CEO of Parallel6 Inc. and is a U.S. Naval Academy graduate with further studies at Harvard Business School.

Antonio Santidrian, Ph.D., Chief Scientific Officer, leads all research and development initiatives at Calidi and is the coinventor of the company’s CLD-201 (Supernova) and CLD-400 (RTNova) platforms. Since joining Calidi in 2015, he has applied his 20+ years of expertise in academia and biotech, focusing on anti-cancer translational research, to drive the company’s innovative drug pipeline. Before Calidi, Dr. Santidrian led translational studies at The Scripps Research Institute, advancing treatments for breast cancer metastasis, and contributed to the development of ACADRA for chronic lymphocytic leukemia (CLL) at the University of Barcelona, Spain.

Boris Minev, M.D., President of Medical and Scientific Affairs, is a renowned physician-scientist with expertise in Immuno-Oncology, stem cell biology, and oncolytic viruses. Previously, Dr. Minev served as Director of Immunotherapy and Translational Oncology at Genelux Corporation and remains an adjunct professor at the Moores UCSD Cancer Center. His background includes research at the National Cancer Institute.

Andrew Jackson, CFO, has held executive finance roles with experience in biotech and clinical-stage companies, including Eterna Therapeutics and Ra Medical Systems. Mr. Jackson holds an MSBA in Finance from San Diego State University and a BSB in Accounting from the University of Minnesota.

Calidi Biotherapeutics Inc. (NYSE American: CLDI), closed Wednesday's trading session at $6.18, off by 14.7586%, on 268,425 volume. The average volume for the last 3 months is 3,473,461 and the stock's 52-week low/high is $2.4324/$46.68.

Recent News

• Calidi Biotherapeutics Inc. (NYSE American: CLDI) - New Genetic Discovery Could Boost Cancer Immunotherapy
• TinyGemsBreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Fast Track Designation for CLD-201 in Soft Tissue Sarcoma
• BioMedNewsBreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces 1-for-12 Reverse Stock Split Effective August 5

PowerBank Corporation (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN)

The QualityStocks Daily Newsletter would like to spotlight PowerBank Corporation (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN).

PowerBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) , announced the installation of its first 4.99 MW Battery Energy Storage System (BESS) at the SFF-06 project site in Cramahe, Ontario, marking its official entry into the battery storage sector. Backed by a $25.8 million green loan from RBC and acquired through a $45 million transaction with Solar Flow-Through Funds Ltd., the project is 50% owned by PowerBank and 50% by First Nations partners. The system benefits from a 22-year IESO contract with premium pricing and qualifies for a 30% Clean Technology Investment Tax Credit. Civil and electrical work is being executed by Anvil Crawler under a $1.85 million contract. While progress continues at SFF-06, development of the related 903 project remains delayed due to pending municipal approvals and local opposition, prompting a notice of potential force majeure to the IESO.

To view the full press release, visit https://ibn.fm/wUQXH

PowerBank Corporation (NASDAQ: SUUN) (CSE: SUNN) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the United States. The company is committed to advancing the transition to sustainable energy by offering end-to-end services that include project origination, financing structuring, engineering, procurement, construction, and long-term operations and maintenance. PowerBank focuses on delivering innovative energy solutions through solar photovoltaic systems, battery energy storage systems (BESS), and electric vehicle (EV) charging infrastructure.

With a vision to provide scalable and reliable clean energy solutions, PowerBank has established itself as a leader in the renewable energy market by cultivating partnerships with utilities, commercial and industrial entities, municipalities, and residential customers. Its vertically integrated business model allows for optimized efficiency, cost management, and returns across diverse markets in North America. This end-to-end approach ensures greater control over project quality, costs, and operational outcomes, strengthening its competitive position.

Driven by a mission to create a greener future, PowerBank manages a robust portfolio of projects, including more than 100 megawatts (MW) of developed capacity and a pipeline exceeding one gigawatt (GW). The company’s commitment to sustainability and innovation makes it a recognized player in the renewable energy sector.

PowerBank has offices in Toronto, Ontario and New York.

Projects

PowerBank boasts an impressive and diverse portfolio of renewable energy initiatives that underline its leadership in the clean energy space. In the U.S., the company has over 250 MW of solar projects under development, principally in New York, focusing on community solar farms and commercial and industrial installations. Notably, PowerBank is developing several community solar projects in upstate New York, which will deliver clean energy to local residents and small businesses. Community solar projects, which are a cornerstone of PowerBank’s portfolio, provide scalable solutions for renters, homeowners, and small businesses to access affordable renewable energy, driving localized energy independence and economic savings.

In Canada, PowerBank has been a significant participant in Ontario’s Feed-in-Tariff program, where it has secured contracts for close to 200 MW of capacity. Its current management includes 70 solar power projects, totaling 28.8 MW of operational solar assets. The company’s expertise extends to the development and ownership of battery energy storage systems and EV charging stations, further diversifying its portfolio.

The company’s vertically integrated approach spans the entire project lifecycle, from initial site acquisition and grid interconnection to long-term operation and maintenance services. This ensures seamless execution and high-quality outcomes, providing value to stakeholders and supporting the transition to a clean energy future.

Market Opportunity

PowerBank operates within a growing renewable energy market driven by global demand for sustainable power solutions. In North America, favorable policies such as the Inflation Reduction Act in the United States and Canada’s investments in green technologies provide a robust foundation for renewable energy adoption. Solar PV installations and battery energy storage systems are at the forefront of this expansion, addressing energy reliability and grid stability while reducing carbon emissions.

The North American solar PV market was valued at $25.02 billion in 2019 and is projected to reach $120.74 billion by 2027, growing at a compound annual growth rate (CAGR) of 21.7% from 2020 to 2027. Likewise, the global BESS market is expected to expand from $7.8 billion in 2024 to $25.6 billion by 2029, at a CAGR of 26.9%, as reported by MarketsandMarkets. These trends are driven by the increasing integration of renewable energy sources, the need for grid resilience, and declining technology costs.

PowerBank’s operations have it well-positioned to capitalize on these opportunities. With a development pipeline exceeding one gigawatt (GW), the company is focused on meeting growing demand in community and commercial solar sectors. Decentralized energy solutions, such as virtual net metering and behind-the-meter systems, further enhance PowerBank’s market potential by addressing the critical need for flexible, cost-effective, and sustainable energy infrastructure. By leveraging its vertically integrated model and diversified portfolio, PowerBank stands as a key player in driving the renewable energy transition.

Leadership Team

Dr. Richard Lu, MD, MSc., MHSc., MBA, serves as President and CEO of PowerBank, bringing over 25 years of global energy experience. His leadership has been instrumental in advancing the company’s strategic initiatives across North America, Europe, and Asia, with a focus on renewable energy development and operational excellence.

Sam Sun, MBA, is the Chief Financial Officer of PowerBank. A Chartered Professional Accountant with more than 15 years of expertise in corporate finance, Mr. Sun has overseen financial strategies and internal controls across the cleantech, manufacturing, and mining sectors in Canada, the U.S., and China.

Andrew van Doorn, PE, serves as Chief Operating Officer, with nearly three decades of experience in engineering and construction. Mr. van Doorn has successfully led projects totaling over 200 MW of solar capacity and is a former Chairman of the Canadian Solar Industries Association.

Tracy Zheng, MBA, Chief Development Officer, has over 25 years of experience in brand marketing, business development, and solar project operations. She has spearheaded sales initiatives, conducted feasibility studies, and negotiated key partnerships that drive PowerBank’s growth.

Matt Wayrynen, Executive Chairman and Director, has a background in resource company management, venture capital, and mergers and acquisitions. Under his leadership, Solar Flow-Through Funds, where Mr. Wayrynen acted as CEO, was acquired by PowerBank, enhancing its asset portfolio and growth prospects.

---

Forward Looking Statements

This report contains forward-looking statements and forward-looking information ‎within the meaning of Canadian securities legislation (collectively, “forward-looking ‎statements”) that relate to the Company’s current expectations and views of future events. ‎Any statements that express, or involve discussions as to, expectations, beliefs, plans, ‎objectives, assumptions or future events or performance (often, but not always, through the ‎use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will ‎continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, ‎‎”projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be ‎forward-looking statements and may involve estimates, assumptions and uncertainties ‎which could cause actual results or outcomes to differ materially from those expressed in ‎such forward-looking statements. In particular and without limitation, this report ‎contains forward-looking statements pertaining to the Company’s expectations regarding its industry trends and overall market growth of the data center market; the Company’s expansion into the data center market, including its pursuit of opportunities as a developer, owner, and strategic partner in data center infrastructure; supporting the demand for high-performance, sustainable energy solutions within the sector; details of the company’s business plan including development of solar power projects, battery storage projects and EV charging projects; the completion of any contracts for, or construction of, any data center, solar power, battery storage or EV projects; the receipt of interconnection approval, permits and financing to be able to construct projects; the receipt of incentives for projects; and the size of the Company’s development pipeline. No assurance ‎can be given that these expectations will prove to be correct and such forward-looking ‎statements included in this report should not be unduly relied upon. These ‎statements speak only as of the date of this report.‎

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. In making the forward looking statements included in this report, the Company has made various material assumptions, including but not limited to: obtaining the necessary regulatory approvals; that regulatory requirements will be maintained; general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and services offered by the Company’s competitors; that the Company’s current good relationships with its service providers and other third parties will be maintained; and government subsidies and funding for renewable energy will continue as currently contemplated. Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and the Company cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements.

Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Forward-‎Looking Statements” and “Risk ‎Factors” in the Company’s most recently completed Annual Information Form, and other public filings of the Company, which include: the Company may be adversely affected by volatile solar power market and industry conditions; the execution of the Company’s growth strategy depends upon the continued availability of third-party financing arrangements; the Company’s future success depends partly on its ability to expand the pipeline of its energy business in several key markets; governments may revise, reduce or eliminate incentives and policy support schemes for solar and battery storage power; general global economic conditions may have an adverse impact on our operating performance and results of operations; the Company’s project development and construction activities may not be successful; developing and operating solar projects exposes the Company to various risks; the Company faces a number of risks involving Power Purchase Agreements (“PPAs”) and project-level financing arrangements; any changes to the laws, regulations and policies that the Company is subject to may present technical, regulatory and economic barriers to the purchase and use of solar power; the markets in which the Company competes are highly competitive and evolving quickly; an anti-circumvention investigation could adversely affect the Company by potentially raising the prices of key supplies for the construction of solar power projects; foreign exchange rate fluctuations; a change in the Company’s effective tax rate can have a significant adverse impact on its business; seasonal variations in demand linked to construction cycles and weather conditions may influence the Company’s results of operations; the Company may be unable to generate sufficient cash flows or have access to external financing; the Company may incur substantial additional indebtedness in the future; the Company is subject to risks from supply chain issues; risks related to inflation; unexpected warranty expenses that may not be adequately covered by the Company’s insurance policies; if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the renewable energy market; there are a limited number of purchasers of utility-scale quantities of electricity; compliance with environmental laws and regulations can be expensive; corporate responsibility may adversely impose additional costs; the future impact of any resurgence of COVID-19 on the Company is unknown at this time; the Company has limited insurance coverage; the Company will be reliant on information technology systems and may be subject to damaging cyberattacks; the Company may become subject to litigation; there is no guarantee on how the Company will use its available funds; the Company will continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions that will dilute the current shareholders; and future dilution as a result of financings.

The Company undertakes no obligation to update or revise any ‎forward-looking statements, whether as a result of new information, future events or ‎otherwise, except as may be required by law. New factors emerge from time to time, and it ‎is not possible for the Company to predict all of them, or assess the impact of each such ‎factor or the extent to which any factor, or combination of factors, may cause results to ‎differ materially from those contained in any forward-looking statement. Any forward-‎looking statements contained in this report are expressly qualified in their entirety by ‎this cautionary statement.‎

PowerBank Corporation (NASDAQ: SUUN), closed Wednesday's trading session at $1.31, up 1.5504%, on 95,365 volume. The average volume for the last 3 months is 176,980 and the stock's 52-week low/high is $1.23/$6.43.

Recent News

• PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) - TechMediaBreaks - PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Installs 4.99 MW Battery Storage System in Ontario 
• Biogas Could Be the Unsung Hero in Transitioning to Clean Energy
• PowerBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103): Name Change Signals Broader Energy Strategy and Investor Growth Potential

Lantern Pharma Inc. (NASDAQ: LTRN)

The QualityStocks Daily Newsletter would like to spotlight Lantern Pharma Inc. (NASDAQ: LTRN).

Lantern Pharma has introduced an AI-powered module within its RADR(R) platform to assess DDA-DDRi combination therapies.

The module uses genomic, transcriptomic, and clinical data, to predict treatment synergy and patient response, and supported the design of Lantern's FDA-cleared Phase 1B/2 trial in triple-negative breast cancer.

A review of 221 clinical trials informed the development of the predictive algorithm.

Non-PARP DDRi combinations with DNA-damaging agents showed strong outcomes in specific cancer subtypes.

Lantern is evaluating licensing opportunities to commercialize the module for broader oncology use.

Lantern Pharma (NASDAQ: LTRN) announced that its wholly owned subsidiary, Starlight Therapeutics, has received FDA clearance for an Investigational New Drug ("IND") application to initiate a Phase Ib/2a clinical trial of STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme ("GBM") at first progression. The study will evaluate safety, tolerability and preliminary efficacy in recurrent GBM, a highly aggressive brain cancer with limited treatment options. STAR-001 is a brain-penetrant DNA-damaging agent designed to exploit DNA repair deficiencies through synthetic lethality, and its effect is enhanced by spironolactone, which induces NER deficiency in tumor cells. The therapy has received both Orphan Drug and Fast Track designations from the FDA. The program builds on data from an ongoing Phase 1a trial and is being advanced using Lantern's AI-driven RADR(R) platform to identify optimal patient populations and accelerate development timelines.

To view the full press release, visit https://ibn.fm/8ndAq

Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR® (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. The company has gained 11 FDA Designations for its portfolio of drug candidates including: Fast Track, Orphan and Pediatric Rare Disease. The company’s data-driven approach enables rapid identification of promising drug candidates and the design of targeted clinical trials for specific patient subpopulations and cancer types.

Lantern’s vision is to transform cancer treatment by integrating large-scale genomics, AI-based biomarker discovery, and preclinical modeling to accelerate the development of oncology drugs. The company’s pipeline includes three lead small molecule candidates and an antibody-drug conjugate (ADC) program across 12 cancer indications, supported by strategic collaborations with global research institutions and clinical partners. The company has three active clinical trials enrolling patients with multiple clinical milestones expected throughout the next twelve months.

The company’s mission is centered on transforming the cost and pace of developing innovative therapies for patients with genetically defined cancers or limited treatment options. Lantern is also advancing brain and CNS cancer drug development through its wholly owned subsidiary, Starlight Therapeutics.

The company is headquartered in Dallas, Texas.

Product Portfolio

Lantern Pharma’s product pipeline consists of three lead candidates—LP-300, LP-184, and LP-284—and a preclinical ADC program. All are guided by insights from the RADR® platform, which has grown to incorporate over 200 billion oncology-specific data points.

LP-300 is in a Phase 2 trial (Harmonic™) for non-small cell lung cancer (NSCLC) in never smokers. The trial evaluates LP-300 in combination with carboplatin and pemetrexed and has shown a clinical benefit rate of 86% and an objective response rate of 43% in its initial cohort. The study is enrolling 90 patients across the U.S., Japan, and Taiwan (NCT05456256).

LP-184 is in a Phase 1a trial for advanced solid tumors and GBM (NCT05933265). The compound has received FDA Fast Track Designations for GBM and triple-negative breast cancer (TNBC), as well as four Rare Pediatric Disease Designations. Upcoming Phase 1b/2 trials are planned for TNBC (monotherapy and with olaparib) and for NSCLC patients with KEAP1/STK11 mutations in combination with nivolumab and ipilimumab.

LP-284 is currently in a Phase 1 trial for relapsed or refractory non-Hodgkin’s lymphoma (NHL) and other solid tumors (NCT06132503). The drug candidate has demonstrated complete tumor suppression in preclinical models of mantle cell lymphoma resistant to Ibrutinib and bortezomib and showed synergistic activity with rituximab in high-grade B-cell lymphoma models.

Lantern’s ADC program is based on cryptophycin conjugates and is undergoing preclinical evaluation, showing sub-nanomolar potency and improved targeting in HER2-expressing models.

The company has also launched Starlight Therapeutics, focused on CNS cancers, where STAR-001 (LP-184 for CNS cancers) is advancing toward a Phase 1b/2 trial in glioblastoma and pediatric brain cancers, including ATRT, supported by Rare Pediatric Disease Designations and preclinical validation from Johns Hopkins.

Market Opportunity

Lantern Pharma is focused on oncology indications with significant unmet medical need and multi-billion-dollar commercial potential.

• LP-300 targets non-small cell lung cancer in never smokers, a patient population estimated at over 150,000 cases globally and representing a market opportunity exceeding $4 billion annually.
• LP-184 is positioned for use in DDR-deficient tumors such as pancreatic, bladder, and triple-negative breast cancers, which collectively represent a U.S. market opportunity estimated at over $10 billion annually. Opportunities in targeted DDR-deficient tumors include the KEAP1/STK11 mutant NSCLC population targeted by LP-184, with a market potential of over $2 billion annually, and TNBC, which alone represents a $4 billion global market given its aggressiveness and high brain metastasis rate.
• LP-284 is aimed at relapsed or refractory non-Hodgkin’s lymphomas, particularly mantle cell lymphoma and HGBL, within a market sized at $3.5 to $4 billion globally.
• CNS cancers addressed by Starlight Therapeutics further expand Lantern’s reach, representing an estimated $5 billion annual global opportunity, including both adult and pediatric cancers.

Leadership Team

Panna Sharma, President, Chief Executive Officer, and Director, leads Lantern Pharma with a deep background in oncology-focused biotechnology and artificial intelligence. He is responsible for Lantern’s strategic vision and has driven the growth of its AI-powered drug development platform. Prior to joining Lantern in 2018, he served as President and CEO of Cancer Genetics Inc. (NASDAQ: CGIX), where he raised over $100 million and expanded the company from 25 to over 250 employees across multiple continents. Earlier, he founded TSG Partners and played a key role in the IPO of iXL, a digital strategy firm.

David R. Margrave, Chief Financial Officer and Secretary, has served in executive roles in life sciences for over two decades. Before joining Lantern, he held leadership positions at BioNumerik Pharmaceuticals, including President and Chief Administrative Officer. He has also been a strategic consultant to multiple biotech firms and served as Senior Legal Advisor at MedCare Investment Corporation. Mr. Margrave holds a dual degree in Economics and Petroleum Engineering from Stanford University and a J.D. from The University of Texas School of Law.

Kishor G. Bhatia, Ph.D., Chief Scientific Officer, has more than 40 years of experience in cancer biology, including leadership at the National Cancer Institute where he served as Director of the AIDS Malignancy Program and held key roles in cancer treatment and diagnosis. He has also worked as an Adjunct Investigator and consultant to biotech firms such as Reprocell and Cancer Genetics. Dr. Bhatia earned his Ph.D. in Biochemistry from the University of Mumbai and completed postdoctoral research at Johns Hopkins University. He is a Fellow of the Royal College of Pathology in the UK.

Lantern Pharma Inc. (NASDAQ: LTRN), closed Wednesday's trading session at $5.14, off by 1.1538%, on 270,964 volume. The average volume for the last 3 months is 510,145 and the stock's 52-week low/high is $2.55/$6.118.

Recent News

• Lantern Pharma Inc. (NASDAQ: LTRN) - Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations
• BioMedNewsBreaks - Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial 
• AINewsBreaks - Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy

Bollinger Innovations, Inc. (NASDAQ: BINI)

The QualityStocks Daily Newsletter would like to spotlight Bollinger Innovations, Inc. (NASDAQ: BINI).

Mullen Automotive recently brought all of its EV products and brands together under one strong and unified identity — Bollinger Innovations.

The pivot to one commercial EV brand comes amid mounting demand for electrification in delivery, logistics and municipal vehicle fleets.

The company's new identity is also trading under new Nasdaq stock symbol NASDAQ: BINI.

The company's move under one brand clarifies market positioning, creating cohesion across product lines ready to service the commercial vehicle industry.

Bollinger Innovations (NASDAQ: BINI) , formerly known as Mullen Automotive, has completed a major corporate transformation, officially rebranding and switching its NASDAQ ticker from MULN to BINI ( https://ibn.fm/2bEWf ). The updated identity aligns the company's commercial electric vehicle ("EV") offerings, including its Class 1 cargo van and Class 3 and 4 cab chassis trucks, under the unified Bollinger brand and emphasizes its commitment to serving the U.S. commercial mobility market with domestically manufactured EVs.

Bollinger Innovations (NASDAQ: BINI) , an electric vehicle manufacturer, announced $7,500 in additional price adjustments for commercial customers purchasing existing inventory of its Mullen ONE and Mullen THREE EVs. With MSRPs now set at $27,000 and $61,000 respectively, the incentive—combined with a $7,500 Inflation Reduction Act credit for deliveries before September 30—positions both models as high-value options in the Class 1 and Class 3 commercial EV segments. Formerly known as Mullen Automotive, the company recently rebranded and will relabel the vehicles under Bollinger Motors beginning in the 2026 model year. The product lineup also includes the Bollinger B4 Class 4 truck, with a Class 5 model expected in 2027.

To view the full press release, visit https://ibn.fm/qvrBp

Toyota has long been known for its careful and slow approach when it comes to electric vehicles. For years, the company focused more on hybrid models rather than fully electric ones. However, recent developments show that Toyota is now gradually changing direction and starting to take electric vehicles more seriously. One of the biggest signs of this shift is the launch of the new C-HR+ model, which joins Toyota's existing electric vehicle, the bZ4X. This move shows that the company is beginning to accept the fact that the future of cars is electric. According to reports, Toyota has bigger plans ahead, especially in Europe. Even so, Toyota is not planning to switch fully to electric overnight. The company still sees value in its hybrid models and plans to keep improving them. Battery weight and limited driving range remain challenges for full EVs, especially in larger cars. Because of this, Toyota is likely to continue using advanced hybrid technology alongside its electric vehicle plans. In short, Toyota is reembracing electric vehicles with a smart and steady plan, carefully balancing innovation with practicality. For American firms like Bollinger Innovations, Inc. (NASDAQ: BINI) looking to spread their wings internationally, they will have Toyota and other legacy brands to contend with.

Bollinger Innovations, Inc. (NASDAQ: BINI) is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with United States-based manufacturing located in Tunica, Mississippi.

In August 2023, Mullen began commercial vehicle production in Tunica. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The Company’s commercial dealer network consists of Papé Kenworth, Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key West Coast, Midwest, Pacific Northwest, New England, and Mid-Atlantic markets.

In September 2022, Bollinger Motors, of Oak Park, Michigan, became a majority-owned EV truck company of Mullen Automotive. Bollinger Motors has passed numerous milestones including its B4, Class 4 electric truck production launch on Sept. 16, 2024, and the development of a world-class dealer network with over 50 locations across the United States for sales and service support.

Mullen Commercial

Mullen is defining a new era in commercial vehicles with its connected and customized solutions aimed at making businesses more efficient and profitable.

Mullen ONE Class 1 EV Cargo Van

The Mullen ONE class 1 commercial electric vehicle is the first of its kind in the U.S. market. This van was designed to navigate within narrow urban streets and residential roads, all while maximizing payload and cargo space. The Mullen ONE’s height is less than 6.5 feet, meaning your driver can park the vehicle in a residential garage.

Mullen THREE Class 3 Electric Truck

The efficient urban utility low cab forward features a tight turning diameter of 38 feet and excellent visibility for superior maneuverability on narrow city streets. Even in reverse, maneuverability is a breeze with our standard backup camera and 7-inch display screen. This versatile chassis provides a clean top-of-rail for easy upfitting with bodies up to 14 feet long and over 5,300 lbs of payload. In addition, the design of the LCF chassis allows more cargo length within a given overall length.

Mullen Commercial EVs are eligible for several federal and state level EV incentives, which can be combined for maximized savings.

Mullen ONE:

• $7,500 Federal Tax Credit
• $3,500 MOR-EV Incentive (Massachusetts only)
• $7,500 ComEd Business & Public Sector EV Rebate Program (Illinois only)

Mullen THREE:

• $7,500 Federal Tax Credit
• $45,000 California’s Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (HVIP) (California only)
• $15,000 MOR-EV Incentive (Massachusetts only)
• $30,000 ComEd Business & Public Sector EV Rebate Program (Illinois only)

In the last two years, Mullen has conducted over 100 vehicle demos or pilots across various industries in the U.S. resulting in significant progress, including new sales opportunities and vehicle orders received and or completed:

• Universities: Princeton University, University of Virginia (UVA), University of California, Los Angeles (UCLA)
• Local city governments: Cities of Dublin, Ohio, Raleigh, North Carolina, Los Angeles, California, Seattle, Washington and Orange County, North Carolina
• Small businesses: From local florist shops to health care providers delivering supplies

Mullen has an extensive dealer network in the U.S. with renowned dealers nationwide including:

• Papé Group (California, Oregon, Washington)
• National Auto Fleet Group (California)
• Pritchard EV (Iowa)
• Eco Auto (Massachusetts)
• Ziegler Truck Group (Minnesota)
• Range Truck Group (Washington)
• Mullen Commercial Vehicle Center (California)

Mullen Commercial EVs are available for purchase on Sourcewell under NAFG’s Sourcewell Contract # 091521-NAF which offers Class 1-3 light duty trucks, cars, vans, SUVs, cab chassis, and electric vehicles with related equipment and accessories to U.S. government agencies.

Bollinger Motors

Mullen entered the medium-duty truck classes through its September 2022 acquisition of a controlling interest in EV truck innovator Bollinger Motors. The acquisition gave Mullen access to a significant pipeline of interest from large companies for commercial electric truck classes 3-6 in a wide range of markets, such as last-mile delivery, refrigeration, utilities and upfitters.

The 2025 Bollinger B4 chassis cab is an all-new, all-electric Class 4 commercial truck designed from the ground up with extensive fleet and upfitter input. Bollinger’s unique chassis design protects the 158-kWh battery pack and components to offer unparalleled capability and safety in the commercial market. The vehicle also features a payload in excess of 7,300 pounds with an average driving range of 185 miles. Bollinger Motors began serial production of the B4 on Sept. 16 via its manufacturing partnership with Roush Industries at their facility in Livonia, Michigan.

Bollinger Motors has passed numerous milestones in recent months, including:

• 30 B4s delivered and paid for, worth nearly $4.5 million, since start of production
• Its production launch on Sept. 16 at Roush Industries in Livonia, Michigan
• Achieving FMVSS compliance
• Receiving the Certificate of Conformity from the Environmental Protection Agency, and CARB certification
• The creation of a world-class dealer and service network
• An agreement with Our Next Energy in Novi, Michigan, for battery packs
• Providing a full warranty coverage of the B4 chassis cab
• Announcing Syncron as its warranty administration partner and Amerit Fleet Solutions as its mobile service provider
• A partnership with EO to power EV charging infrastructure, equipment and technology solutions for Bollinger’s dealers and customers

Bollinger Motors has qualified for multiple federal and state incentive programs, including:

• Inflation Reduction Act incentives of up to $40,000 per vehicle
• California: Innovative Small e-Fleet (ISEF) Pilot Program, with incentives up to $120,000 per vehicle
• Massachusetts: voucher of up to $30,000 per vehicle from Massachusetts Offers Rebates for Electric Vehicles (MOR-EV)
• New York: up to $100,000 from NYTVIP through NYSERDA
• Pennsylvania: up to a $20,000 grant from Alternative Fuels Incentive Grant Program (AFIG) of the Pennsylvania Department of Environmental Protection

Mullen FIVE RS

The Mullen FIVE RS is an ultra-high-performance EV Crossover featuring a top speed of over 200 mph and acceleration from 0-60 mph in under 2 seconds. The FIVE RS is equipped with 800-volt architecture, all-wheel drive, two-speed gearbox, and over 1,100 horsepower.

The Mullen FIVE RS is planned for launch in Germany with vehicle sales planned for December 2025. Initial vehicle market territories include the EU in 2025, followed by the UAE and South Africa in early 2026.

Mullen is partnering with Faissner Petermeier Fahrzeugtechnik AG (“FPF”), which has decades of experience in the development and production of serial components and sophisticated vehicles for global brands such as Piech Automotive, Gumpert Automotive and is in partnership with BMW of all the above. FPF is certified according to the IATF standard and fulfills all the special requirements of the Federal Motor Transport Authority in Germany.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

Mullen is led by an executive team with extensive EV, OEM and high-growth startup experience.

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working towards a sustainable future by creating a suite of clean-energy, electric vehicles at varied price points. With entirely US based manufacturing and operations, Mr. Michery is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Bollinger Innovations, Inc. (NASDAQ: BINI), closed Wednesday's trading session at $2.97, off by 35.8531%, on 3,103,688 volume. The average volume for the last 3 months is 759,801 and the stock's 52-week low/high is $2.9/$13500000000.

Recent News

• Bollinger Innovations, Inc. (NASDAQ: BINI) - UN Chief Explains Why Transitioning to Clean Energy is Smart Economics
• Study Compares Whether EV Battery Reuse is Better Than Recycling 
• BYD Celebrates Reaching 13 Million NEVs Milestone 

Wearable Devices Ltd. (NASDAQ: WLDS)

The QualityStocks Daily Newsletter would like to spotlight Wearable Devices Ltd. (NASDAQ: WLDS).

Wearable Devices (NASDAQ: WLDS, WLDSW) , a developer of AI-powered touchless sensing wearables, announced the launch of a military-focused project to advance human-machine interface (HMI) technology. The initiative aims to deliver a neural control system enabling soldiers to operate tactical systems through intuitive gestures without physical contact. Powered by the company's proprietary neural interface and AI-driven sensors, the technology is designed to enhance battlefield efficiency and safety. This move reinforces Wearable Devices' leadership in neural input innovation and expands its reach into the defense sector.

To view the full press release, visit https://ibn.fm/pq9Q1

Wearable Devices Ltd. (NASDAQ: WLDS) is a growth-stage technology company pioneering the next generation of human-computer interaction through AI-powered neural input wearables. Mudra, its proprietary wrist-worn technology, enables touchless, gesture-based control of digital devices, offering users a seamless, intuitive interface through subtle finger and hand movements. Since introducing its technology to the market in 2014, the company has pursued both business-to-business (B2B) and business-to-consumer (B2C) strategies through a dual-channel model.

The company believes the future of technology should begin with the human. Wearable Devices envisions decoding the human body to enable context-aware AI-powered technology that listens, learns, and adapts – to us.

The company envisions a future where human intent becomes the language of technology. Through non-invasive neural sensing and adaptive algorithms, the company enables more natural, personalized, and intuitive interactions with computers.

The company is headquartered in Yokneam Illit, Israel.

Products

Neural control has entered the market: commercially available since 2023 with the Mudra Band and already used by thousands of users worldwide. With its product line, including Mudra Band and Mudra Link, the company has introduced the world’s first wrist-worn neural interfaces, enabling intuitive, touchless control through natural micro-gestures: subtle finger movements and wrist flicks. Whether streaming media, controlling smart devices, or interacting with AR glasses, Mudra brings neural input into everyday life.

This early adoption isn’t just validation — it’s acceleration. With real users engaging in real environments, the company is learning fast, improving faster, and shaping a product that grows more refined with every interaction.

Mudra Band

Mudra Band is the company’s flagship B2C product, designed as a sleek, aftermarket accessory for the Apple Watch. It uses patented sEMG sensors to detect neural signals from the wrist and translates them into real-time digital commands. This allows users to control and streamline interactions between the iPhone, iPad, MacBook, and Apple TV using familiar micro-gestures like taps, pinches, or swipes — all without touching a screen.

The device features a high-resolution analog front end, IMU integration, adaptive machine learning, and ergonomic form factors for all-day comfort. Users can toggle between multiple Apple devices using the Mudra Band’s dedicated Apple Watch face, enabling a fully connected, touchless experience. The Mudra Band is optimized for low-latency, high-accuracy interactions and supports a wide range of digital applications. The Mudra Band received a CES 2021 Innovation Award.

Mudra Link

Mudra Link expands the company’s reach beyond the Apple ecosystem, offering compatibility with Android, Windows, and AR/XR platforms. The product includes the innovative Gesture Mapper feature, allowing users to assign personalized commands to gestures such as tap, pinch, flick, or twist. This functionality replaces or augments traditional input methods, supporting media controls, pointer input, and full directional mapping. A key feature of Mudra Link is its dual-mode input system (mouse mode or D-pad mode), empowering users to personalize control schemes across devices, operating systems, and user interfaces.

Mudra Link is recognized for its ergonomic design, lightweight build, and plug-and-play ease of use. It supports native integration with AR glasses from leading manufacturers and received a CES 2025 Innovation Award.

Mudra DevKit and Integration

In parallel with its consumer devices, Wearable Devices offers a Mudra Developer Kit (MDK) and integration program for enterprise and OEM partners. The MDK includes full-stack tools (hardware bands, SDK, APIs, and sample code) that allow developers and original equipment manufacturers to embed Mudra’s neural sensing capabilities into their own products and applications. For example, an AR headset maker can integrate Mudra’s sensors to enable native hand-gesture input, or a software developer can use Mudra’s API to track user gestures for novel interactions.

The MDK supports both Android and iOS and even provides real-time neural raw signal monitoring for research and prototyping. This B2B offering not only expands Mudra technology into new environments such as industrial automation, robotics, and gaming peripherals, but also fosters a broader ecosystem of Mudra-powered solutions. By lowering the barrier for others to adopt its AI gesture recognition engine, Wearable Devices accelerates innovation and garners strategic relationships.

The MDK and related licensing offerings illustrate Wearable Devices’ push-pull strategy: selling consumer products today, while seeding ‘Mudra inside’ into other companies’ devices tomorrow.

Market Opportunity & Strategy

Wearable Devices operates at the intersection of neural interfaces, wearable computing, and the rapidly expanding AR/XR sector. According to MarketsandMarkets, the global AR and VR market is projected to grow from $22.12 billion in 2024 to $96.32 billion by 2029, at a CAGR of 34.2%. The rising demand for natural, hands-free input methods positions neural wearables like Mudra as foundational components in spatial computing and smart environments.

Additionally, the health monitoring wearables market is gaining traction as neural biosignals become a promising data source. The company’s LMM (Large Motor Unit Action Potential Model) platform is being explored for predictive health monitoring, cognitive state tracking, and performance analytics. Government-level support, such as advocacy from the U.S. Secretary of Health and Human Services, further validates the sector’s momentum.

Combined with patent-protected technology and strategic alliances with companies like Qualcomm, TCL-RayNeo™, and Media Exceed, Wearable Devices is well-positioned to capture value across consumer, enterprise, and healthcare verticals.

The company’s phased market strategy anticipates this:

• Phase 1 – Enthusiast Consumer Adoption: Introduce Mudra Band as an add-on for Apple Watch (tapping into a passionate user base of early adopters and tech enthusiasts). Achieve proof-of-concept and get market feedback. This phase built brand credibility and seeded a community of users.
• Phase 2 – Expand Platform & Ecosystem: Launch Mudra Link for all users and open the Mudra SDK to developers and B2B partners. Focus on the XR/AR market and tech-savvy consumers, while enabling enterprise use-cases through the Developer Kit and strategic partnerships. The company is actively showcasing its tech to industry leaders and integrating with their platforms.
• Phase 3 – Leverage Data & Enter New Verticals: With a growing user base, Wearable Devices is collecting an invaluable dataset of neural signals and usage patterns. If data is the new oil for AI, neural signals will power the next computing revolution — enabling machines to understand human intent in real time. This fuels its Large Motor-Unit Action Potential Model (LMM) – a bio-signal intelligence platform that continuously learns from neural data to improve accuracy and enable new applications. One major new vertical is digital health and wellness: Wearable Devices is adapting its tech to track physiological and cognitive indicators from the wrist. Because the Mudra sensors capture muscle activation signals, they can potentially detect patterns related to stress, fatigue, focus, and even early signs of health conditions before traditional symptoms appear, and Wearable Devices recently announced it is expanding LMM into predictive health monitoring and cognitive analytics. This means the company could offer solutions for workplace productivity (measuring alertness), athletic training (muscle fatigue analytics), or preventive healthcare (flagging neuromuscular irregularities) – vastly broadening its addressable market. Through monitor applications, the vision is to go from controlling devices to also understanding the user, providing actionable bio-insights. The LMM platform’s AI continuously adapts to each individual’s neural profile, enabling truly personalized and proactive applications.
• Phase 4 – Ubiquitous Adoption via B2B Integration: Finally, Wearable Devices plans to drive mass adoption by aligning with major consumer tech players. By making its Mudra Data Platform available to enterprises, OEMs, and app developers, the company positions itself as the backbone for neural interaction services. By “laying the groundwork for the next neural frontier”, Wearable Devices is ensuring that when the tech giants move to adopt neural input, its platform is the mature, data-rich standard ready to be deployed.

Through these phased efforts, Wearable Devices balances B2C and B2B paths. It generates near-term revenues and user feedback via direct consumer product sales, while simultaneously developing long-term enterprise relationships and intellectual property value. This dual model not only diversifies revenue streams but also reinforces the technology’s credibility: consumer adoption demonstrates demand and usability, which in turn attracts enterprise interest, creating a virtuous cycle.

Leadership Team

Asher Dahan, Chief Executive Officer, co-founded Wearable Devices Ltd. in 2014 and has served as CEO and director since 2016. He is a seasoned executive with proven expertise in strategic planning, project execution, and business leadership. Asher oversees the company’s operations and resources, guiding major corporate decisions and long-term vision. Prior to founding Wearable Devices, he held engineering and leadership roles at Intel Haifa, specializing in high-speed interface validation. He holds a BSc in Electrical Engineering from Ort Braude College.

Guy Wagner, Chief Scientific Officer and President, co-founded Wearable Devices Ltd. in 2014 and has served on its board since inception. As CSO and President, Guy leads the company’s technological innovation and scientific direction. He is the main inventor behind the company’s core technology and brings multidisciplinary expertise in hardware design, biomedical signal processing, embedded programming, and sensor systems. He previously worked at Intel as a hardware engineer and holds a BSc in Electrical Engineering from Ort Braude College.

Leeor Langer, co-founder and CTO since 2016, is a leading expert in algorithms, machine learning, and signal and image processing. He has held senior R&D roles in the medical imaging and digital security sectors, including at Intel, and brings deep academic and industry experience. Leeor has authored several scientific papers and holds a BSc from the Technion and an MSc in Applied Mathematics from Tel Aviv University, graduating cum laude.

Wearable Devices Ltd. (NASDAQ: WLDS), closed Wednesday's trading session at $1.67, off by 2.0528%, on 634,078 volume. The average volume for the last 3 months is 100,112 and the stock's 52-week low/high is $1.195/$38.8.

Recent News

• Wearable Devices Ltd. (NASDAQ: WLDS) - AINewsBreaks - Wearable Devices Ltd. (NASDAQ: WLDS, WLDSW) Launches AI-Powered Touchless Neural Control Project for Military Use
• TechMediaBreaks - Wearable Devices Ltd. (NASDAQ: WLDS, WLDSW) Secures Continuation Patent for Gesture and Voice-Control Interface
• Wearable Devices Ltd. (NASDAQ: WLDS) Is 'One to Watch'

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT).

The FDA-cleared HeartBeam system enables patients and physicians to access significant arrhythmia data outside traditional clinical settings.

The HeartBeam system, credit card–sized and fully portable, represents a breakthrough in ambulatory cardiac care.

Beyond ambulatory arrhythmia assessment, the platform is poised for future advancements, including synthesized 12-lead ECG generation.

Foundational clearance from the U.S. Food and Drug Administration ("FDA") for its patented HeartBeam system has proved pivotal for HeartBeam (NASDAQ: BEAT) , a cardiac technology company focused on transforming the cardiac-care space ( https://ibn.fm/0TAG4 ). The first cable-free, high-fidelity ECG device that captures the heart's electrical activity from three distinct directions, the HeartBeam system enables patients and physicians to access critical arrhythmia data outside traditional clinical settings.

HeartBeam Inc. (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. The company is creating the first ever cable-free synthesized 12-lead ECG platform designed to give patients the ability to record their symptoms the moment they occur, wherever they are. By providing synthesized, 12-lead ECG data, physicians can quickly assess the symptoms and ensure patients get the care they need in a timely manner. It also eliminates the need for wires, complex setup, or clinical staff, thus allowing synthesized 12-lead ECG signals to be accessible outside of a medical setting.

HeartBeam’s vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, accuracy of conventional 12-lead ECGs for arrhythmia detection but also unlocks future capabilities in ischemia detection, AI-assisted analysis, and longitudinal cardiac trend tracking.

The HeartBeam System is now FDA cleared for arrhythmia assessment, following foundational 510(k) clearance granted in December 2024. The company submitted a 510(k) application for its 12-lead ECG synthesis software in January 2025 for arrhythmia assessment. As it approaches commercialization, HeartBeam is executing a multi-phase go-to-market strategy with initial U.S. rollout plans and a focus on high-margin, recurring revenue.

The company is headquartered in Santa Clara, California.

Products

HeartBeam’s flagship product is a credit card-sized, cable-free device designed to capture ECG signals in three non-coplanar directions and transform them into synthesized 12-lead ECGs. This novel form factor integrates a smartphone app, cloud connectivity, and a physician portal, enabling patients to record cardiac events at the moment symptoms occur and physicians to assess and triage in near real time.

The device is supported by an expanding software ecosystem. A key component of this is HeartBeam’s proprietary 12-lead ECG synthesis software, which met its clinical endpoint in the VALID-ECG pivotal study with 93.4% manual diagnostic agreement for arrhythmia assessment. This software is currently under FDA review and is designed to deliver clinical-grade arrhythmia diagnostic capabilities outside of traditional healthcare environments.

In April 2025, HeartBeam announced a strategic partnership with AccurKardia to incorporate its FDA-cleared ECG analysis software, AccurECG™, into HeartBeam’s offering. This integration is expected to enhance automated rhythm interpretation, streamline physician workflows, and improve diagnostic speed and accuracy.

Additional form factors are under development, including an on-demand synthesized 12-lead patch with issued patents, intended to serve the extended-wear market segment. These complementary offerings are intended to support chronic disease management and continuous monitoring applications, broadening HeartBeam’s total product ecosystem in the future.

Market Opportunity

HeartBeam is targeting large and growing segments within the $20 billion+ global cardiac monitoring and diagnostics market. According to the company’s own materials, the U.S. concierge care segment alone represents a $500 million serviceable addressable market (SAM), comprising approximately 1.5 million patients—500,000 of whom are at elevated cardiac risk. This initial focus provides a strategic entry point for cash-pay and early adoption.

Expanding beyond this niche, HeartBeam identifies a $1.3 billion to $2.6 billion annual opportunity in the broader U.S. direct patient pay market, driven by more than 2.6 million high-income individuals aged 35–74 with elevated cardiac risk. For comparison, more than 2.5 million Oura rings and over 3 million AliveCor Kardia devices have been sold, demonstrating strong consumer willingness to adopt personal cardiac technologies.

HeartBeam’s long-term opportunity is significantly larger. The company estimates that over 20 million people in the U.S. are at high risk for myocardial infarction (MI), representing a total addressable market nearly 40 times greater than the concierge segment. Additionally, the company’s on-demand 12-lead patch aims to capture market share in the extended wear and mobile cardiac telemetry (MCOT) space, competing with incumbents like iRhythm, Boston Scientific, Philips, and Baxter.

Leadership Team

Robert P. Eno, Chief Executive Officer and Director, brings over 30 years of experience launching disruptive medical technologies and leading commercialization efforts. He has held executive roles at HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular, and holds an MBA and BA from Stanford University.

Branislav Vajdic, PhD, President and Founder, is a seasoned innovator with over three decades of experience in technology and device development. He co-invented flash memory at Intel and led engineering teams responsible for the Pentium processor series. He previously served as CEO of NewCardio and holds a PhD in Electrical Engineering from the University of Minnesota.

Timothy Cruickshank, Chief Financial Officer, has over 15 years of experience in financial and strategic leadership roles. Formerly CFO at ImpediMed, he transformed the company into a SaaS-driven model. He holds an MBA from Keller Graduate School and a BS in Accounting from Syracuse University.

Peter J. Fitzgerald, MD, PhD, Chief Medical Officer, is a Stanford professor emeritus and interventional cardiologist with leadership in over 175 clinical trials and 24 medical startups. He co-founded TriVentures and has advised the FDA for over 20 years.

Ken Persen, Chief Technology Officer, has more than 25 years of experience in cardiac and digital health technology, including founding LIVMOR and leadership roles at Guidant and Cameron Health. He specializes in system design and product engineering for connected cardiac solutions.

HeartBeam Inc. (NASDAQ: BEAT), closed Wednesday's trading session at $0.9497, off by 4.7442%, on 99,306 volume. The average volume for the last 3 months is 72,012 and the stock's 52-week low/high is $0.9451/$3.48.

Recent News

• HeartBeam Inc. (NASDAQ: BEAT) - HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care
• HeartBeam Inc.'s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics
• BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Schedules Aug. 13 Call to Discuss Q2 Results and Provide Business Updates

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) s a critical metals technology company developing scalable rare earth element (“REE”) refining infrastructure in North America. Originally founded in 2006 as a mineral exploration company, Ucore has since evolved into a processing technology innovator focused on commercializing its proprietary RapidSX™ platform under a $18.4 million contract from the U.S. Department of Defense, with additional support from Natural Resources Canada. The company’s flagship deployment is the Louisiana Strategic Metals Complex (“SMC”), with additional SMCs planned to follow.

Ucore’s mission is to help reestablish a domestic REE supply chain by offering competitive, modular processing solutions that reduce dependence on China. Supported by government funding, private capital, and engineering partnerships, Ucore aims to meet growing demand for rare earth oxides in electric vehicles, defense systems, and advanced energy technologies.

The company is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Separation Technology

RapidSX™ is Ucore’s proprietary rare earth separation platform, delivering three times faster processing than traditional solvent extraction (SX) methods. Its current demonstration program in Kingston, Ontario, is being conducted under contract with the U.S. Department of Defense to prove commercial readiness for processing both heavy and light REEs. The project is also supported by Natural Resources Canada.

RapidSX™ employs a column-based design that eliminates the need for powered mixer-settlers, enabling a smaller facility footprint, quicker commissioning, and lower CAPEX and OPEX. The platform is adaptable to light and heavy REE feedstocks and is structured for modular scale-up.

The 52-stage RapidSX™ Commercial Demonstration Plant in Kingston, Ontario—operated in partnership with Kingston Process Metallurgy—has logged thousands of runtime hours and is currently processing rare earth feedstock further to the company’s U.S. Department of Defense contract. In January 2025, Ucore secured a $500,000 non-dilutive grant from Ontario’s Critical Minerals Innovation Fund to support the advancement of the Kingston facility and, in the words of Ontario Mines Minister George Pirie, “build a secure supply chain ready to fuel the technologies of tomorrow.”

Strategic Metals Complex – Louisiana

Ucore has selected an 80,800-square-foot brownfield site within the England Airpark in Alexandria, Louisiana, as the location for its first commercial rare earth refining facility. The Louisiana SMC is expected to scale from 2,000 tonnes per annum (TPA) of total rare earth oxides initially to 5,000 TPA, with potential to ultimately reach 7,500 TPA.

The facility benefits from Foreign Trade Zone (FTZ) status, reducing tariff burdens on imported inputs and enhancing logistics efficiency. In addition to these structural advantages, the state of Louisiana has outlined an incentive package valued at $15 million, including a $900,000 infrastructure grant and $360,000 in additional local support. The project is expected to create 100 family-wage jobs and has received strong support from federal and state officials.

To date, Ucore has secured $2.3 million in milestone payments under its $18.4 million OTA award from the U.S. Department of Defense. In early 2024, the company also secured C$2.16 million in private investment from Hondo Private Equity to support its commercialization efforts.

Bokan-Dotson Ridge REE Project – Alaska

Ucore maintains 100% ownership of the Bokan-Dotson Ridge heavy REE project in Southeast Alaska. A Preliminary Economic Assessment was completed in January 2013. The Alaska Industrial Development and Export Authority (AIDEA) has authorized $145 million in bond financing under SB99 (2014) to support future development.

While Bokan remains a long-term asset, Ucore continues to advance it at a measured pace, complementing its near-term focus on commercial rare earth refining and oxide production at the Louisiana SMC.

Market Opportunity

According to Grand View Research, the global rare earth elements market was estimated at $3.95 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030. The market outlook remains strong, fueled by the growing demand for permanent magnets and catalysts in the automotive sector.

In March 2025, President Trump invoked the Defense Production Act to prioritize domestic critical mineral production, signaling a national mandate to reduce reliance on “hostile foreign powers’ mineral production.” One month later, the Chinese government enacted immediate export restrictions on seven key rare earth elements, including dysprosium and terbium, further intensifying pressure on Western nations to develop secure and independent supply chains. This underscores the strategic value of Ucore’s domestic separation infrastructure.

Leadership Team

Pat Ryan, P.Eng., Chairman and CEO, is the founder of Neocon International, a leading automotive OEM supplier. He brings over 25 years of experience in global supply chain innovation and has led Ucore since 2014 in its strategic pivot toward rare earth processing.

Peter Manuel, Vice President, CFO & Corporate Secretary, has served as Ucore’s financial lead for 14 years. Trained as a Chartered Accountant, with extensive experience across Canada, England, and Ireland, Mr. Manuel has advised public and private entities on strategic planning, treasury, and assurance.

Michael Schrider, MEng, P.E., Vice President & COO, is a multidisciplinary engineer with over 30 years of experience. He founded and operated engineering firms SAi and ABD and has overseen all phases of Ucore’s technical development since 2016.

Geoff Atkins, Vice President of Business Development, has 30 years of mining experience and was instrumental in advancing both Lynas’ Mt. Weld and Vital Metals’ Nechalacho REE operations. He brings deep operational knowledge and leads feedstock strategy at Ucore.

Ucore Rare Metals Inc. (OTCQX: UURAF), closed Wednesday's trading session at $1.984, up 21.7178%, on 1,885,846 volume. The average volume for the last 3 months is 618,090 and the stock's 52-week low/high is $0.33/$1.99.

Recent News

• Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) - Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Set to Leverage Proprietary Tech, New Trade Deals as Magnetic Materials Gatekeeper
• MiningNewsBreaks - Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) Spotlighted by Bloomberg for Upcoming Launch of Louisiana Rare Earths Plant 
• MiningNewsBreaks - Ucore Rare Metals Inc.'s (TSX.V: UCU) (OTCQX: UURAF) RapidSX(TM) Core to Blueprint to Secure Rare Earth Independence

BluSky AI Inc. (OTC: BSAI)

The QualityStocks Daily Newsletter would like to spotlight BluSky AI Inc. (OTC: BSAI).

BluSky AI Inc. (OTC: BSAI) is pioneering the next generation of AI infrastructure through modular, rapidly deployable data centers that meet the escalating compute demands of artificial intelligence, machine learning, and high-performance computing. The company’s mission is to empower AI innovators by eliminating infrastructure bottlenecks and accelerating time-to-compute with energy-efficient, scalable solutions.

Rather than betting on individual AI applications, BluSky AI addresses the universal need for compute power—positioning itself as a foundational layer in the AI revolution. Its infrastructure-first approach enables clients to focus on innovation while the company delivers the critical backbone powering tomorrow’s breakthroughs.

BluSky AI is headquartered in Salt Lake City, Utah.

Products

BluSky AI’s core offering is its SkyMod series of modular data centers—pre-assembled, scalable compute units designed specifically for AI workloads. The flagship SkyMod One delivers 1 MW of compute power in a compact 1,400-square-foot footprint, while the SkyMod XL offers 1.7 MW in 3,000 square feet. These units are fully assembled off-site, tested, and shipped ready for plug-and-play deployment either on BluSky-owned land or client facilities.

SkyMod modules integrate NVIDIA GPUs and are optimized for high-density AI applications such as generative AI, large language models, inference engines, and scientific computing. Built for rapid scaling and high efficiency, each system includes advanced cooling, secure infrastructure, and dynamic workload balancing to support evolving client needs.

The company’s data centers are engineered for sustainability, incorporating renewable energy sources like solar, wind, and geothermal where available. By deploying on powered land assets, BluSky AI shortens lead times and lowers costs, creating a fast, flexible alternative to traditional monolithic data centers.

Market Opportunity

The global data center market was valued at $347.6 billion in 2024 and is projected to reach $652.0 billion by 2030, growing at a CAGR of 11.2%, driven by the rapid expansion of AI, machine learning, and IoT adoption, according to Grand View Research. As enterprises demand faster, more scalable compute solutions, modular infrastructure like BluSky AI’s SkyMod series offers a compelling alternative to legacy data center models.

With North America accounting for over 40% of the global market and the U.S. expected to grow at a 10.7% CAGR from 2025 to 2030, BluSky AI is well-positioned to capture demand for AI-optimized infrastructure that can be deployed rapidly and cost-effectively. By focusing on GPU-centric, modular deployments tied to energy infrastructure, the company addresses a growing gap between compute demand and deployment speed in the AI era.

Leadership Team

Trent D’Ambrosio, Chief Executive Officer, is a seasoned executive with a track record in telecommunications, hedge fund management, and natural resource development. He previously sold the first transatlantic fiber cable, built a successful gold mining company, and now leads BluSky AI with a vision to revolutionize AI infrastructure through strategic energy integration and rapid deployment.

Julien Bedard, Chief Technology Officer, is a pioneering technologist known for launching the first Bitcoin escrow and anti-fraud service. At BluSky AI, he oversees cloud architecture, cybersecurity, infrastructure automation, and the development of AI-native data center technology, ensuring scalability and resilience across deployments.

Dan Gay, Chief Operating Officer, has Fortune 500 executive leadership in telecom, technology, and energy, as well as start-up experience with finance and blockchain companies. At MCI and Qwest, he launched new service and sales centers, and directed National Account Sales. He has been a successful CMO in brand creation, product development, partnerships, and revenue generation programs to expand company awareness, sales, and revenue.

BluSky AI Inc. (OTC: BSAI), closed Wednesday's trading session at $11, up 21.0121%, on 7,224 volume. The average volume for the last 3 months is 8,210 and the stock's 52-week low/high is $0.118/$17.97.

Recent News

• BluSky AI Inc. (OTC: BSAI) - TechMediaBreaks - BluSky AI Inc. (OTC: BSAI) Signs LOI to Acquire 15 Acres in Arizona for Modular AI Expansion
• InvestorNewsBreaks - BluSky AI Inc. (OTC: BSAI) to Acquire Land and 50MW Power Access for Delta Data Center Development
• BlueSky AI Inc. (BSAI) Advances Modular Data Center Strategy with New Partnership

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF)

The QualityStocks Daily Newsletter would like to spotlight Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF).

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) is a medical device company advancing dedicated imaging solutions to improve the screening, diagnosis, and treatment of breast cancer. Focused exclusively on this clinical area, Izotropic is developing purpose-built technologies designed to address persistent limitations in conventional breast imaging. Through innovation in both device architecture and image acquisition, the company aims to enhance diagnostic confidence while improving patient experience.

Izotropic’s mission is to deliver transformative tools that empower radiologists, reduce missed cancers, and streamline clinical workflows. By introducing a next-generation imaging platform for breast cancer screening and diagnosis, the company is targeting a clear unmet need in a multibillion-dollar global market. Its vision centers on redefining how breast imaging is performed—shifting away from adaptations of whole-body scanners or 2D mammography toward a fully dedicated approach optimized for breast anatomy.

The company’s strategy is built around a singular platform with expansion potential. Izotropic is focused on commercializing its lead product through a staged pathway that includes regulatory authorization, clinical validation, and strategic investor engagement. In parallel, the company is developing educational tools and communications platforms to raise awareness among patients, clinicians, and stakeholders about the evolving role of dedicated breast imaging technologies in cancer care.

The company is headquartered in Vancouver, British Columbia, with operations in Sacramento, California.

Technology Portfolio

Izotropic’s flagship product is the IzoView Breast CT Imaging System, a dedicated breast imaging platform offering high-resolution, true 3D visualization without compression. The IzoView system was advanced from academic innovation to commercial readiness by Izotropic’s in-house team, building on exclusively licensed technology developed at the University of California, Davis to optimize diagnostic accuracy, patient comfort, and clinical workflow. IzoView integrates proprietary mechanical design, patented hardware innovations, and trade-secret software algorithms, along with AI-driven enhancements designed to improve radiologist performance.

Now in clinical-ready form and housed at Izotropic’s engineering facility in Sacramento, California, IzoView was built under an ISO 13485-compliant quality management system. It is scheduled for use in the company’s planned U.S. clinical trial for FDA market authorization. The device is also central to the company’s broader commercialization strategy, which includes platform extensions and future imaging-based product lines outlined in its recently completed 150-page business plan and financial model.

In preparation for launch, Izotropic is also rolling out strategic awareness platforms. These include a company-hosted podcast and the development of breastct.com, a new educational resource to support patients, clinicians, and stakeholders. These initiatives are designed to enhance engagement, reinforce brand positioning, and build early market traction for IzoView.

Market Opportunity

Izotropic is targeting the global breast imaging market, which is undergoing rapid innovation as healthcare providers seek more accurate, patient-friendly alternatives to traditional mammography. Current screening technologies have well-documented limitations in detecting tumors in women with dense breast tissue, a challenge IzoView directly addresses.

According to a report by MarketsandMarkets, the breast imaging market is projected to grow from $4.3 billion in 2023 to $6.6 billion by 2028, at a compound annual growth rate (CAGR) of 8.9%. Key drivers include the increasing prevalence of breast cancer, the shift toward early detection, and advances in imaging technology such as AI integration and contrast-enhanced diagnostics.

Izotropic’s licensing structure with UC Davis allows the company to pursue either FDA or CE Mark approval, offering flexibility for U.S. and international market entry. Izotropic’s go-to-market plan is supported by ongoing education efforts and a structured clinical strategy, both aligned to accelerate adoption and unlock value in a growing global market.

Leadership Team

Robert Thast, Interim CEO, is the founding executive of Izotropic and has over 30 years of experience leading public companies. He has raised over $100 million in capital, built cross-functional leadership teams, and guided early-stage ventures through public listings and strategic transitions. At Izotropic, he oversees corporate development, financing, and market strategy.

Dr. John Boone, Ph.D., Principal Founder and Director, is a Distinguished Professor of Radiology and Biomedical Engineering at UC Davis. He is a pioneer in breast CT development, having built and tested four dedicated scanners and led trials with nearly 500 women. He has held top roles in AAPM and RSNA and currently serves as Editor-in-Chief of Medical Physics.

Ralph Proceviat, CPA, CFO and Director, brings more than four decades of experience in finance, restructuring, and cross-border operations. He has served as CEO, President, and CFO across multiple sectors and has raised significant capital for both public and private ventures. He is also the founder of C-Suite-Consulting.

Dr. Younes Achkire, Ph.D., Chief Operating Officer and Lead Engineer, is the technical lead behind IzoView. He previously co-founded Zap Surgical Systems and has commercialized FDA-cleared technologies in medtech and clean energy. At Izotropic, he manages engineering, manufacturing, clinical deployment, and operational scale-up.

Izotropic Corp. (OTCQB: IZOZF), closed Wednesday's trading session at $0.2205, up 13.0769%, on 27,306 volume. The average volume for the last 3 months is 29,290 and the stock's 52-week low/high is $0.0186/$0.33.

Recent News

• Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) - BioMedNewsBreaks - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Market Demand for Breast CT Imaging Innovation
• TechMediaBreaks - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights IzoView Breast CT Advantages Over Existing Imaging Technologies 
• Why Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Is 'One to Watch'

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Wednesday's trading session at $3.2, up 7.3826%, on 1,681,760 volume. The average volume for the last 3 months is 17,697,594 and the stock's 52-week low/high is $1.09/$5.4.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Editorial on Rare Disease Therapeutics 
• Study Finds That Inflammation Markers in Diabetics Influence Depression Treatment Outcomes 
• InvestorNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Achieves Biological Efficacy in Phase 2a SGX945 Study for Behçet's Disease